Dm in-depth

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/26

flashcard set

Earn XP

Description and Tags

Vocabulary flashcards covering the basic considerations, monitoring, insulin preparations, and non-insulin medications for diabetes based on Chapter 48.

27 Terms

1
New cards

Type 1 Diabetes (T1D)

A form of diabetes accounting for approximately 5%5\% of cases, characterized by autoimmune destruction of pancreatic beta cells, absolute insulin deficiency, and a mandatory requirement for insulin replacement.

2
New cards

Type 2 Diabetes (T2D)

The most prevalent form of diabetes, accounting for 90%90\% to 95%95\% of diagnosed cases, resulting from a combination of cellular insulin resistance and impaired insulin secretion.

3
New cards

Prediabetes

A metabolic state defined by an impaired fasting plasma glucose of 100100 to 125 mg/dL125\,mg/dL or an impaired 22-hour oral glucose tolerance test result of 140140 to 199 mg/dL199\,mg/dL, increasing the risk for T2D and cardiovascular disease.

4
New cards

Hemoglobin A1c

A standard blood test that measures the percentage of glycated hemoglobin to provide an index of average blood glucose control over the prior 22 to 33 months.

5
New cards

Estimated Average Glucose (eAG)

A value reported in mg/dLmg/dL calculated from Hemoglobin A1c percentage using the formula eAG=28.7×A1c−46.7eAG = 28.7 \times A1c - 46.7.

6
New cards

Self-Monitoring of Blood Glucose (SMBG)

The standard day-to-day blood glucose monitoring method using capillary blood, recommended for all patients receiving insulin to guide dosage adjustments.

7
New cards

Continuous Glucose Monitoring (CGM)

A monitoring technology using a worn sensor that measures interstitial glucose levels every 55 minutes for 1010 to 1414 days.

8
New cards

Short-Duration: Rapid-Acting Insulin

Insulin human analogs (lispro, aspart, glulisine) characterized by a rapid onset (1010 to 30 minutes30\,minutes) and short duration (33 to 6 hours6\,hours), administered subcutaneously right before meals to control postprandial hyperglycemia.

9
New cards

Regular Insulin

Unmodified short-acting human insulin (Humulin R, Novolin R) administered subcutaneously 30 minutes30\,minutes before meals or intravenously for glycemic management in emergency and inpatient settings.

10
New cards

Neutral Protamine Hagedorn (NPH) Insulin

An intermediate-duration insulin created by conjugating regular insulin with protamine to delay absorption, administered subcutaneously twice daily to provide basal glycemic control between meals and overnight.

11
New cards

Insulin Glargine (U-100)

A long-acting human insulin analog that forms microprecipitates upon subcutaneous injection to steadily release insulin over up to 24 hours24\,hours without a sharp peak.

12
New cards

Insulin Degludec

An ultra-long-acting human insulin analog available in U-100 and U-200 concentrations that provides steady, peakless basal glycemic control for in excess of 24 hours24\,hours.

13
New cards

Metformin

The preferred first-line biguanide oral antidiabetic drug that lowers blood glucose by inhibiting hepatic glucose production, reducing intestinal glucose absorption, and increasing tissue insulin sensitivity.

14
New cards

Lactic Acidosis

A rare, potentially fatal complication of metformin accumulation caused by inhibition of mitochondrial lactic acid oxidation, presenting with hyperventilation, myalgia, malaise, and unusual somnolence.

15
New cards

Sulfonylureas

A class of oral antidiabetic secretagogues (glipizide, glyburide, glimepiride) that stimulate pancreatic beta-cell insulin release by blocking ATP-sensitive potassium channels.

16
New cards

Meglitinides (Glinides)

Short-acting oral insulin secretagogues (repaglinide, nateglinide) taken within 30 minutes30\,minutes before meals to facilitate calcium influx and stimulate rapid pancreatic insulin release.

17
New cards

Thiazolidinediones (Glitazones / TZDs)

Oral antidiabetic agents (pioglitazone) that activate nuclear PPAR-gamma receptors to reduce insulin resistance and increase glucose uptake in skeletal muscle and adipose tissue.

18
New cards

Alpha-Glucosidase Inhibitors

Oral drugs (acarbose, miglitol) that inhibit brush-border alpha-glucosidase in the small intestine, slowing complex carbohydrate digestion to decrease postprandial glucose spikes.

19
New cards

Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Gliptins)

Oral drugs (sitagliptin, saxagliptin, linagliptin, alogliptin) that inhibit DPP-4 to prevent incretin degradation, boosting glucose-dependent insulin release and suppressing glucagon.

20
New cards

Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors

Oral antidiabetic drugs (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, bexagliflozin) that block glucose reabsorption in renal tubules, increasing urinary glucose excretion.

21
New cards

GLP-1 Receptor Agonists (Incretin Mimetics)

Injectable drugs (exenatide, liraglutide, dulaglutide, semaglutide) that activate GLP-1 receptors to slow gastric emptying, stimulate glucose-dependent insulin release, suppress glucagon, and reduce appetite.

22
New cards

Tirzepatide

A dual GIP and GLP-1 receptor agonist injected subcutaneously once weekly that enhances insulin release, decreases hepatic glucose output, increases satiety, and promotes significant weight loss.

23
New cards

Pramlintide

A synthetic amylin mimetic injected subcutaneously immediately before major meals in T1D or T2D to delay gastric emptying and suppress glucagon secretion.

24
New cards

Diabetic Ketoacidosis (DKA)

A severe, rapid-onset hyperglycemic crisis seen mainly in T1D, characterized by hyperglycemia (>250 mg/dL>250\,mg/dL), ketoacid production, metabolic acidosis, hemoconcentration, and fruity-smelling breath.

25
New cards

Hyperosmolar Hyperglycemic State (HHS)

A gradual-onset hyperglycemic crisis occurring mainly in T2D, characterized by extreme hyperglycemia (>600 mg/dL>600\,mg/dL), severe dehydration, and high plasma osmolality (>320 mOsm>320\,mOsm) without ketoacidosis.

26
New cards

Glucagon

A pancreatic alpha-cell polypeptide hormone administered parenterally or intranasally to reverse severe hypoglycemia by stimulating hepatic glycogenolysis and gluconeogenesis.

27
New cards

Polycystic Ovary Syndrome (PCOS)

An endocrine-metabolic disorder in females characterized by androgen excess and insulin resistance, which can be managed off-label with metformin to improve ovulation and insulin sensitivity.